The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Caorsi, Roberta, Lepore, Loredana, Zulian, Francesco, Alessio, Maria, Stabile, Achille, Insalaco, Antonella, Finetti, Martina, Battagliese, Antonella, Martini, Giorgia, Bibalo, Chiara, Martini, Alberto, Gattorno, Marco
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://ncbi.nlm.nih.gov/pubmed/23442610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4184
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados